UBS Maintains Buy on Inspire Medical Systems, Lowers Price Target to $322
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Danielle Antalffy maintains a Buy rating on Inspire Medical Systems (NYSE:INSP) but lowers the price target from $405 to $322.
September 06, 2023 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS maintains a Buy rating on Inspire Medical Systems but lowers the price target from $405 to $322.
The news is directly related to Inspire Medical Systems. While the Buy rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100